a spanish human proteome project (shpp) la cristalera, miraflores de la sierra, madrid, august...

A Spanish Human Proteome Project (sHPP)

La Cristalera, Miraflores de la Sierra, Madrid, August 28-29th, 2012

Juan P Albar, ProteoRed-ISCIII, CNB-CSIC

A SPANISH HUMAN PROTEOME PROJECT (SHPP)Preliminary proposal

Index1.Introduction

International context Chromosome/gene centric approach The HPP technological pillars Protein annotation and database compilation

•The Spanish Participation in the Human Proteome Project•General and Specific Aims

General aims Specific aims

•Members of the Spanish Consortium Description of the groups ProteoRed presence in the Spanish consortium

•Working Plan Work package list Work package description

•Financing•Spanish Consortium Structure•Benefit for Spain

Spanish HPP Consortium: Current Developments on the

Characterization of the Proteins Encoded by the Chromosome 16"

5th C-HPP Consortium WorkshopThe Chromosome-Centric Human Proteome Project

May 5, 2012, Beijing

Juan-Pablo Albar (Chair)Francisco Blanco (Co-Chair)Fernando Corrales (Co-Chair)

A Spanish Human Proteome Project (sHPP)Preliminary proposal

San Sebastian, July 9th, 2012

Juan P Albar, ProteoRed-ISCIII, CNB-CSIC

The Human Proteome Project Launch

Sydney HUPO2010 23 September 2010

Geneva HUPO201112 September 2011

Sydney September 23 Human Proteome Project

The Mission of the HPP

HPP will deliver a comprehensive map of the human proteins in their biological context. HPP will provide tools for the scientific community that will allow each scientist to design experiments in a better way, as the Human Genome Project did. HPP will inspire, beyond the scientific community, other stakeholders for diagnosis, prevention, therapy and cure of diseases and improved health worldwide.


A gene-centric proteome project

Map the human proteins (gene by gene):

• Molecular (isoforms)

• Sub-cellular (localization)

• Cells, tissues and organs (expression)

• Interaction networks

• Plasma/serum (abundance)

Use all available technology platforms:

• Mass spectrometry

• Antibodies (immunotechnologies)

• Gene fusions (GFP)


C-HPP teams by April 24th, 2012. The C-HPP Consortium internal information

HPP technologic pillars

Legrain et al. MCP 2011

Flow of the overall procedures of the C-HPP work

Spanish HPP Consortium: Current Developments on the

Characterization of the Proteins Encoded by the Chromosome 16"

5th C-HPP Consortium WorkshopThe Chromosome-Centric Human Proteome Project

May 5, 2012, Beijing

Juan-Pablo Albar (Chair)Francisco Blanco (Co-Chair)Fernando Corrales (Co-Chair)

Chromosome 16

1.Bioinformatic analysis of chromosome 16.2.Cell type(s) selection. Trascriptomic and proteomic detailed analysis.3.Expression, purification and characterization of proteins encoded by chromosome 16 that have not been described so far.4.Development of MRM methods for the quantification of the most abundant protein species encoded by each of the chromosome 16 genes.5.Identification, characterization and quantification of protein variants from chromosome 16 genes.6.Definition of SOP7.Development of bioinformatic environment.8.Biobanking.9.Configuration of the B-D pilar for the Spanish HPP consortium.

Chromosome 16 general aims

Top 15 Biofunctions represented in chromosome 16. IPA analysis

Genes on Chromosome 16

More than 85 % of protein coding genes of chromosome 16 are expressed in lymphoid cells, epitelial cells and fibroblasts.

OMIM

NEURODEGENERATIVENEURODEGENERATIVE

CANCERCANCER

OBESITYOBESITY

AUTOINMUNE DISEASESMetabolismMitochondriaInflammation

Diseases mapping on Chromosome 16

External repositoriesExternal repositories

Development of bioinformatic environment:Spanish HPP will join the different resources to provide an unique enquiring system

PAtlasPAtlasNProtNProt

GPMDBGPMDB

PRIDEPRIDE

UProtUProtUpcomingUpcoming

Proteomics results

Proteomics results

Data standards submission

(ProteomeXchange)

Data standards submission

(ProteomeXchange)+ +EmsemblEmsembl

• Characterize the transcriptome to define the actual chr16’s gen set expressed and most importantly which genes are not expressed in the three selected cell types.

• Characterize the proteome in detail. • Expression, purification, and characterization of 22 unknown proteins available in NAPPA

collection.• Development of SRM quantitative assays.

Proteins (862) will be distributed in known (562) and unknown groups (300) and the study will be performed along 3 years, starting in 2012 (214 proteins).

Protein packs will be assigned to each of the 8 MRM groups (24), including equal proportion of known (20, with different range of theoretical difficulty) and unknown proteins (4).

Unknown proteins will be first searched by targeted discovery (TD) and relevant information resulting from this studies will be used to design MRM assays. TD groups (9) will analyze 54 proteins the first year.

Each group will use the master sample (this might require the use of synthetic peptides during the refinement steps). TD will be done in all three selected cell lines. Regarding MRM, a pool of the three cell lines will be used for the 20 known proteins. Decision on using a pool or a particular cell line for the unknown proteins will be taken in light of the results from TD.

Once developed, the assays will be validated by 2 additional groups. Finally, the quantitative assay will be set up using heavy peptides.

• Definition of Bioinformatic standards and SOPs.• Definition of Biobanking strategy, standards... in collaboration with the Spanish Biobanking

Platform.

Workplan proposal

2015 2016 2017

Biobanking

Validation of MRM assays (3 groups, immunoreagents, correlation with gene expression)

Clinical samples. Disease-related changes on protein abundance. Biomarkers

Bioinfirmatic study

MRM for 204 proteins MRM for 329 proteins

SOP, bioinformatic procedures, formats, data banks, etc.

2012 2013 2014

Biobanking

MRM for 329 proteins

Validation of MRM assays (3 groups, immunoreagents, correlation with gene expression)

Clinical samples. Disease-related changes on protein abundance. Biomarkers

Chromosome 16 timeline

Transcriptomic study

Master sample

Targeted discovery (300 proteins)

SHPP-16

PlatformC-HPP

PlatformBD-HPP

Proteo-Red/ISCIII

111 Unknow Proteins

735 Know Proteins

BiologyCells/Tissues

Diseases: PathogenesisDiagnosticPrognosisTreatment

BIOBANK/ISCIII

Who we are

• ProteoRed organization has played an active role in the HUPO-PSI activities, always in close relation with the developments and reviews of different MIAPE modules.

• ProteoRed, an initiative for the coordination, integration and development of 20 proteomics facilities placed all over Spain.

http://www.proteored.org

• ProteoRed use to organize and participate in multi-centric studies that aims to evaluate the robustness and reproducibility of different proteomics workflows.

Node 2J. Mato - CIC-bioGUNE

F. Corrales – CIMAJM. Arizmendi - UPV

Central StructureJP. Albar - CNB

J. Mato - CIC-bioGUNEJ. Abian - LP-CSIC/UAB

Assoc. to Node 1I. Casal - CIB

Assoc. To Node 5P. Carrasco - UV

Node 5M. Sánchez del Pino – CIPF

R. Bru - UA

Node6JA. Bárcena - UCO

Node 1JP. Albar - CNB

C. Gil - PCM-UCMA. Marina - CBMSO

Node 4X. Bustelo - CIC

Node 3J. Abian - LP-CSIC/UAB

J. Arribas - HUVHS. Martínez - PCBD. Andreu - UPF

FX. Avilés - IBB UABO. Bachs - UB

*

.

*

-

Assoc. to node 4F.J. Blanco - INIBIC

PortugalAna Coelho - ITQB

Deborah Penque - ProCura

Geneva Jean Charles Sanchez - UG

Geographical organizationGeographical organization

BD-HPP PlatformCoordinator: Francisco J. Blanco

Clinical ResearchBiomarkers (D/P/P/T)

1st Phase: Known Proteins2nd Phase: Unknown Proteins

Cancer Chair:Co-Chair: I. Casal)

Cancer Chair:Co-Chair: I. Casal)

CAIBER/ISCIII

Neurologic DisordersChair: A. Lopez- MunainCo-chair:JM Arizmendi

Rheumatic Diseases: Chair: FJ. BlancoCo-Chair: JP Albar

Rheumatic Diseases: Chair: FJ. BlancoCo-Chair: JP Albar

Obesity Chair: J PrietoCo-Chair: F. Corrales

Obesity Chair: J PrietoCo-Chair: F. Corrales

RETIC of Cancer

CIBERNed RETIC of Rheumatic

CIBER-Obesity

BIOBANK/ISCIII

SHPP-16

Cardiovascular Diseases: Chair: L Rodriguez-PadialCo-Chair: F. Vivanco

Cardiovascular Diseases: Chair: L Rodriguez-PadialCo-Chair: F. Vivanco

RETIC-Cardiov.

Infectiious Diseases: Chair: J FortunCo-Chair: C. Gil

Infectiious Diseases: Chair: J FortunCo-Chair: C. Gil

HOSPITALESHOSPITALES INSTITUTOS DE INVESTIGACIÓNINSTITUTOS DE INVESTIGACIÓN

CENTROS DE INVESTIGACIÓN


REDES COOPERATIVAS

REDES COOPERATIVAS

CANCERDrs C. BELDA & I.

CASAL

CANCERDrs C. BELDA & I.

CASAL

Chr16-HPP Proteomics Platforms

Chr16-HPP Proteomics Platforms

NEUROLOGICAL DISEASES

Dr A. LOPEZ DE MUNAIN

NEUROLOGICAL DISEASES

Dr A. LOPEZ DE MUNAIN

CARDIOVASCULAR DISEASES

Dr F. VIVANCO & JLR: PADIAL

CARDIOVASCULAR DISEASES

Dr F. VIVANCO & JLR: PADIAL

RHEUMATIC & MUSCLOSKELETAL

DISEASESDr. F. BLANCO

RHEUMATIC & MUSCLOSKELETAL

DISEASESDr. F. BLANCO

SPANISH NATIONAL BIOBANK NETWORK-ISCIII

Dr M. MORENTE

SPANISH NATIONAL BIOBANK NETWORK-ISCIII

Dr M. MORENTE

INFECTIOUS DISEASESDrs C. GIL & J. FORTÚNINFECTIOUS DISEASESDrs C. GIL & J. FORTÚN

OBESITY/LIVER DISEASES

Drs J. PRIETO & F. CORRALES

OBESITY/LIVER DISEASES

Drs J. PRIETO & F. CORRALES

HOSPITALESHOSPITALES INSTITUTOS DE INVESTIGACIÓNINSTITUTOS DE INVESTIGACIÓN



REDES COOPERATIVAS

REDES COOPERATIVAS

ASOCIACIONES DE PACIENTESASOCIACIONES DE PACIENTES

MINISTERIO DE INDUSTRIA

MINISTERIO DE INDUSTRIA

MINISTERIO DE ECONOMIA Y

COMPETITIVIDAD

MINISTERIO DE ECONOMIA Y

COMPETITIVIDAD

MINISTERIO DE SANIDADMINISTERIO DE SANIDAD

MINISTERIO DE EDUCACIÓN

MINISTERIO DE EDUCACIÓN

FARMAINDUSTRIAFARMAINDUSTRIA

ASEBIOASEBIO

INVERSIÓN PRIVADA

INVERSIÓN PRIVADA

PLATAFORMAS PROTEÓMICASPLATAFORMAS PROTEÓMICAS

HPPHPP

COMUNIDADES AUTÓNOMAS

COMUNIDADES AUTÓNOMAS

EMPRESAS AFINES

EMPRESAS AFINES

Steering CommitteeSteering Committee

Analytical (C-HPP)Gene/chromosome centricAnalytical (C-HPP)Gene/chromosome centric

B-D initiativesDisease centric

B-D initiativesDisease centricBioinformaticsBioinformatics

MS and Ab based quantitative

methodsOpen access repositories

MS and Ab based quantitative

methodsOpen access repositories

Hallmarks of diseasePotential biomarkers and

therapeutic targets

Hallmarks of diseasePotential biomarkers and

therapeutic targets

Clinical devicesClinical devices

Personalized medicinePersonalized medicine

Design of prototypesQuantitation of target proteinsDesign of prototypesQuantitation of target proteins

MINECOMINECO

PharmasPharmasISCIIIISCIII

BiotechsBiotechs

MINECOMINECO ISCIIIISCIII

CNBUCMCIBFJDCicBioguneCIMACIPFUABPCBVall D’HebronUSALLa PazINIVIC

CNBUCMCIBFJDCicBioguneCIMACIPFUABPCBVall D’HebronUSALLa PazINIVIC

Board of DirectorsBoard of Directors

Project ManagerProject Manager

Technical DirectorTechnical Director Finance DirectorFinance Director

WG 1WG 1

RU1a/1bRU1a/1b

WG 4WG 4

RU 2a/2hRU 2a/2h

Working Groups

Research Units

WG 2WG 2 WG 3WG 3 WG 5WG 5

Executive Committee

RU 3a/3gRU 3a/3g RU 4a/4eRU 4a/4e RU 5a/5gRU 5a/5g

CHROMOSOME-16 CONSORTIUM STRUCTURE

WG 1.-Protein Micro Array & Peptide Standard Team

WG 1.-Protein Micro Array & Peptide Standard Team

RU1a (Protein Micro Array and Protein Expression

Team)

Dr. Manuel FuentesCIC/IBMCC (USAL/CSIC), Salamanca

RU1a (Protein Micro Array and Protein Expression

Team)

Dr. Manuel FuentesCIC/IBMCC (USAL/CSIC), Salamanca

RU1b(Peptide Standard Team)

Dr. Juan P AlbarCNB-CSIC, ProteoRed, Madrid

RU1b(Peptide Standard Team)

Dr. Juan P AlbarCNB-CSIC, ProteoRed, Madrid

Scientific Researchers:Scientific Researchers: Scientific Researchers:F. RoncalM. Lombardía

Scientific Researchers:F. RoncalM. Lombardía

WG 2.-S/MRM-Protein Platform Team WG 2.-S/MRM-Protein Platform Team

RU2aDr. Juan P. AlbarCNB-CSIC, ProteoRed, Madrid

RU2aDr. Juan P. AlbarCNB-CSIC, ProteoRed, Madrid

RU2bDr. Fernando CorralesCIMA-UN ProteoRed, Pamplona

RU2bDr. Fernando CorralesCIMA-UN ProteoRed, Pamplona

RU2cDr. Francesc CanalsV.H.I.O.ProteoRed, Barcelona

RU2cDr. Francesc CanalsV.H.I.O.ProteoRed, Barcelona

RU2dDr. Concha GilPCM-UCMProteoRed, Madrid


RU2e Dr. Manuel Sanchez del PinoUVProteoRed, Valencia

RU2e Dr. Manuel Sanchez del PinoUVProteoRed, Valencia

RU2fDr. Fernando Vivanco / Dr. M.E BarderasFJD,Madrid/HNP, Toledo

RU2fDr. Fernando Vivanco / Dr. M.E BarderasFJD,Madrid/HNP, Toledo

RU2gDr. Francisco BlancoINIBIC, ProteoRed, La Coruña

RU2gDr. Francisco BlancoINIBIC, ProteoRed, La Coruña

RU2hDr. Silvia BarcelóIACS, Zaragoza (Provisional)

RU2hDr. Silvia BarcelóIACS, Zaragoza (Provisional)

Scientific Researchers:M. MarcillaS. GharbiA.AlpízarC. González

Scientific Researchers:M. MarcillaS. GharbiA.AlpízarC. González

Scientific Researchers:Scientific Researchers:







WG 3.-Protein Sequencing TeamWG 3.-Protein Sequencing Team

RU3fDr. Jesus M. ArizmendiUPVProteoRed, Bilbao

RU3fDr. Jesus M. ArizmendiUPVProteoRed, Bilbao

RU3eDr. Ignacio CasalCIB-CSIC, ProteoRed, Madrid

RU3eDr. Ignacio CasalCIB-CSIC, ProteoRed, Madrid

RU3dDr. Eliandre de OliveiraPCB, ProteoRed, Barcelona

RU3dDr. Eliandre de OliveiraPCB, ProteoRed, Barcelona

RU3cDr. Manuel Sanchez del PinoUV, ProteoRed, Valencia

RU3cDr. Manuel Sanchez del PinoUV, ProteoRed, Valencia

RU3bDr. Joaquin AbianIIBB-CSIC ProteoRed, Barcelona

RU3bDr. Joaquin AbianIIBB-CSIC ProteoRed, Barcelona

RU3aDr. José M. Mato / Dr. Félix ElortzaCIC-BioGUNE, ProteoRed, Bilbao

RU3aDr. José M. Mato / Dr. Félix ElortzaCIC-BioGUNE, ProteoRed, Bilbao

RU3gDr. Juan P. AlbarCNB-CSIC, ProteoRed, Madrid

RU3gDr. Juan P. AlbarCNB-CSIC, ProteoRed, Madrid






Scientific Researchers:A.ParadelaR. Navajas

Scientific Researchers:A.ParadelaR. Navajas


WG 4.-Bioinformatics TeamWG 4.-Bioinformatics Team

RU4aDr. Juan P AlbarCNB-CSIC, ProteoRed, Madrid

RU4aDr. Juan P AlbarCNB-CSIC, ProteoRed, Madrid

RU4bDr. Fernando CorralesCIMA-UNProteoRed, Pamplona

RU4bDr. Fernando CorralesCIMA-UNProteoRed, Pamplona

RU4cDr. Joaquin AbianIIBB-CSIC ProteoRed, Barcelona

RU4cDr. Joaquin AbianIIBB-CSIC ProteoRed, Barcelona

RU4eDr. Jesus M. ArizmendiUPVProteoRed, Bilbao

RU4eDr. Jesus M. ArizmendiUPVProteoRed, Bilbao



Scientific Researchers:A.MedinaS. M-Bartolomé

Scientific Researchers:A.MedinaS. M-Bartolomé





WG 5.-Clinical Health Care & Biobanking Team (S_B/D-HPP)

WG 5.-Clinical Health Care & Biobanking Team (S_B/D-HPP)

RU5gDr. Manuel MorenteSNBN, CNIO, Madrid(considered for inclusion in the consortium)

RU5gDr. Manuel MorenteSNBN, CNIO, Madrid(considered for inclusion in the consortium)

RU5dDr. Adolfo López de MunainInst. BiodonostiaS. Sebastian

RU5dDr. Adolfo López de MunainInst. BiodonostiaS. Sebastian

RU5cDr. Rodríguez Padial/ Dr. Fernando Vivanco / Dr. M.E BarderasFJD, Madrid/HNP, Toledo

RU5cDr. Rodríguez Padial/ Dr. Fernando Vivanco / Dr. M.E BarderasFJD, Madrid/HNP, Toledo

RU5bDr. Cristobal BeldaFSB, La Paz Hospital, Madrid (Provisional)

RU5bDr. Cristobal BeldaFSB, La Paz Hospital, Madrid (Provisional)

RU5aDr. Francisco BlancoINIBIC, ProteoRed, La Coruña

RU5aDr. Francisco BlancoINIBIC, ProteoRed, La Coruña




Scientific Researchers:Scientific Researchers: Scientific

Researchers:Scientific Researchers:

RU5fDr. Concha GilPCM-UCMProteoRed, Madrid

RU5fDr. Concha GilPCM-UCMProteoRed, Madrid

RU5eDr. Fernando CorralesCIMA-UN ProteoRed, Pamplona

RU5eDr. Fernando CorralesCIMA-UN ProteoRed, Pamplona

Scientific Researchers:Scientific Researchers: Scientific

Researchers:Scientific Researchers:

WG5-Clinical Health Care & Biobanking TeamRU5a-Dr. Francisco BlancoInstituto de Investigacion Biomedica (INIBIC), ProteoRed, La CoruñaRU5b-Dr. Cristobal Belda (Provisional)Severiano Ballesteros FoundationLa Paz Hospital, MadridRU5c-Dr. Rodriguez Padial/Dr. Fernando Vivanco/ Dr. ME BarderasJimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, ToledoRu5d-Dr. Adolfo López de MunainInstituto Biodonostia, San SebastianRU5e-Dr. Fernando Corrales/J. PrietoCIMA-University of Navarra RU5f-Dr. Concha GilPCM-Computensis University (PCM-UCM), ProteoRed, MadridRU5g-Dr. Manuel Morente (considered for inclusion in the consortium)Spanish National BioBanking NetworkCNIO, Madrid

WG5-Clinical Health Care & Biobanking TeamRU5a-Dr. Francisco BlancoInstituto de Investigacion Biomedica (INIBIC), ProteoRed, La CoruñaRU5b-Dr. Cristobal Belda (Provisional)Severiano Ballesteros FoundationLa Paz Hospital, MadridRU5c-Dr. Rodriguez Padial/Dr. Fernando Vivanco/ Dr. ME BarderasJimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, ToledoRu5d-Dr. Adolfo López de MunainInstituto Biodonostia, San SebastianRU5e-Dr. Fernando Corrales/J. PrietoCIMA-University of Navarra RU5f-Dr. Concha GilPCM-Computensis University (PCM-UCM), ProteoRed, MadridRU5g-Dr. Manuel Morente (considered for inclusion in the consortium)Spanish National BioBanking NetworkCNIO, Madrid

WG4-Bioinformatics TeamRU4a-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, MadridRU4b-Dr. Fernando CorralesCIMA-University of Navarra ProteoRed, PamplonaRU4c-Dr. Joaquin AbianIIBB, CSIC, ProteoRed, BarcelonaRU4d-Dr. Concha GilPCM-Computensis University (PCM-UCM), ProteoRed, MadridRU4e-Dr. Jesus M. ArizmendiBasque Country University, ProteoRed, Bilbao

WG4-Bioinformatics TeamRU4a-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, MadridRU4b-Dr. Fernando CorralesCIMA-University of Navarra ProteoRed, PamplonaRU4c-Dr. Joaquin AbianIIBB, CSIC, ProteoRed, BarcelonaRU4d-Dr. Concha GilPCM-Computensis University (PCM-UCM), ProteoRed, MadridRU4e-Dr. Jesus M. ArizmendiBasque Country University, ProteoRed, Bilbao

WG2-S/MRM-Protein Platform TeamRU2a-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, MadridRU2b-Dr. Fernando CorralesCIMA-University of Navarra, ProteoRed, PamplonaRU2c-Dr. Francesc CanalsVall d'Hebron Institut d'Oncologia (V.H.I.O.),ProteoRed, BarcelonaRU2d-Dr. Concha GilMadrid Science Park-Computensis University (PCM-UCM), ProteoRed, MadridRU2e-Dr. Manuel Sanchez del PinoFelipe Princess Research Center (CIPF), ProteoRed, ValenciaRU2f-Dr. Fernando Vivanco / Dr. ME BarderasJimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, ToledoRU2g-Dr. Francisco BlancoInstituto de Investigacion Biomedica (INIBIC), ProteoRed, La CoruñaRU2h-Dr Silvia BarcelóAragón Health Sciences Institute (IACS), Zaragoza

WG2-S/MRM-Protein Platform TeamRU2a-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, MadridRU2b-Dr. Fernando CorralesCIMA-University of Navarra, ProteoRed, PamplonaRU2c-Dr. Francesc CanalsVall d'Hebron Institut d'Oncologia (V.H.I.O.),ProteoRed, BarcelonaRU2d-Dr. Concha GilMadrid Science Park-Computensis University (PCM-UCM), ProteoRed, MadridRU2e-Dr. Manuel Sanchez del PinoFelipe Princess Research Center (CIPF), ProteoRed, ValenciaRU2f-Dr. Fernando Vivanco / Dr. ME BarderasJimenez Díaz Foundation (FJD), Madrid /National Paraplegics Hospital, ToledoRU2g-Dr. Francisco BlancoInstituto de Investigacion Biomedica (INIBIC), ProteoRed, La CoruñaRU2h-Dr Silvia BarcelóAragón Health Sciences Institute (IACS), Zaragoza

WG1-Protein Micro Array & Peptide Standard TeamRU1a (Peptide standardization Team):Dr. Manuel FuentesCentro de Investigación del Cáncer/IBMCC (USAL/CSIC), SalamancaRU1b (Protein Micro Array and Protein expression Team): Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid

WG1-Protein Micro Array & Peptide Standard TeamRU1a (Peptide standardization Team):Dr. Manuel FuentesCentro de Investigación del Cáncer/IBMCC (USAL/CSIC), SalamancaRU1b (Protein Micro Array and Protein expression Team): Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid

WG3-Protein Sequencing Team RU3a-Dr. José M. Mato / Dr. Félix ElortzaCIC-BioGUNE, ProteoRed, BilbaoRU3b-Dr. Joaquin AbianIIBB, CSIC ProteoRed, BarcelonaRU3c-Dr. Manuel Sanchez del PinoUniversity of Valencia, ProteoRed, ValenciaRU3d-Dr. Eliandre de OliveiraParc Científic de Barcelona (PCB), ProteoRed, BarcelonaRU3e-Dr. Ignacio CasalBiology Research Center-CSIC (CIB-CSIC), ProteoRed, MadridRU3f-Dr. Jesus M. ArizmendiBasque Country University ProteoRed, BilbaoRU3g-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid

WG3-Protein Sequencing Team RU3a-Dr. José M. Mato / Dr. Félix ElortzaCIC-BioGUNE, ProteoRed, BilbaoRU3b-Dr. Joaquin AbianIIBB, CSIC ProteoRed, BarcelonaRU3c-Dr. Manuel Sanchez del PinoUniversity of Valencia, ProteoRed, ValenciaRU3d-Dr. Eliandre de OliveiraParc Científic de Barcelona (PCB), ProteoRed, BarcelonaRU3e-Dr. Ignacio CasalBiology Research Center-CSIC (CIB-CSIC), ProteoRed, MadridRU3f-Dr. Jesus M. ArizmendiBasque Country University ProteoRed, BilbaoRU3g-Dr. Juan P AlbarNational Center for Biotechnology-CSIC (CNB-CSIC), ProteoRed, Madrid

Aims to achieve in the 1st Chr-16 Consortium Meeting

• Evaluation of the strategy defined in the April 2nd S_HPP Meeting: S/MRM, AIMS, Shotgun, cell culture, protein expression, data base, bioinformatics platform, data workflow

• Preparation of JPR manuscript, HUPO-Boston Posters…

• 2012 Working plan (short and medium term)

HUPO CONGRESS POSTERS (I)

• RE: Abstract log #322 Your abstract entitled Chromosome 16 Consortium: Current Developments on the Characterization of the Proteins Encoded by the Chromosome 16" (log #322) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA).

• RE: Abstract log #146 Your abstract entitled Chromosome 16. Transcriptomic profiling of lymphocyte B Ramos cells, MCF-7 epithelial cells and CCD18 fibroblasts (log #146) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA).

• RE: Abstract log #368 Your abstract entitled Profiling the Chromosome 16 by high-resolution data-dependent Mass Spectrometry (log #368) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA).

•

HUPO CONGRESS POSTERS (II)

• RE: Your abstract log# 758 for the HUPO2012 conference was submitted on 6/30/2012.The log number for your abstract is 758. Chromosome 16 Consortium: The Spanish B/D-C-HPP Initiative Juan P Albar; Jesus Fortun; Jesus Mari Arizmendi; Cristobal Belda; Ignacio Casal; Fernando Corrales; Concha Gil; Adolfo Lopez-Munain; Jesus Prieto; Jesus Rodriguez-Padial; Fernando Vivanco; Francisco J Blanco . Spanish B/D-HPP Consortium, A Coruña, Spain.

•RE: Abstract log #217 Your abstract entitled Automatic reporting and reproducibility analysis of ProteoRed participants in the multi-laboratory studies using the “MIAPE extractor” tool (log #217) is formally accepted for poster presentation at the HUPO 11th Annual World Congress, September 9-13, 2012 in Boston, MA (USA).

• RE: Abstract log# 785 Your abstract entitled Reporting and connecting experimental information through proteomics data standards. J. Alberto Medina-Aunon; Salvador Martínez de Bartolomé; Miguel A. López; Juan P. Albar Centro Nacional de Biotecnología - CSIC, Madrid, Spain for the HUPO2012 conference was submitted on 7/11/2012.

a spanish human proteome project (shpp) la cristalera, miraflores de la sierra, madrid, august...

Documents

human proteome projectgeneral

human genome project

hpp hpp

human body

human proteins gene

spainspanish hpp consortium

spanish consortium description

chpp workschematic overview